Ghrelin and leptin response to oral glucose challenge among antipsychotic drug-treated children.
We investigated ghrelin, leptin, glucose, and insulin response to an oral glucose tolerance test among children receiving antipsychotics. Hormone concentrations were assayed at fasting, 30, 60, and 120 minutes. The sample was composed of 9 obese (defined as at or above the 95th percentile for age) and 10 overweight/normal children (defined as less than the 95th percentile in weight) based on National Institutes of Health criteria. Ages of the obese (10.7 +/- 3.4 years) and the overweight/normal (13.1 +/- 1.6 years) did not differ. Leptin was significantly higher among the obese group and did not change consequent to glucose. Ghrelin did not differ between the groups, and when the values were combined, ghrelin decreased at 30 minutes and approached fasting concentrations at 120 minutes. To further explore our data, we constituted separate groups based upon z score changes. When weight gain defined as an increase in z score (X = 0.4), the nongainers showed leptin concentrations to decrease over time. Findings encourage further oral glucose tolerance test studies to explain the leptin response to weight gain seen among children receiving antipsychotic medication.
Winsberg
Bertrand
B
Brookdale University Hospital and Medical Center, Brooklyn, NY, USA.
Usubiaga
Helen
H
Cooper
Tom
T
D000284:Administration, Oral; D000293:Adolescent; D000367:Age Factors; D000704:Analysis of Variance; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000068180:Aripiprazole; D019958:Attention Deficit and Disruptive Behavior Disorders / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D001786:Blood Glucose / Q000378:metabolism; D015992:Body Mass Index; D002648:Child; D002746:Chlorpromazine / Q000008:administration & dosage / Q000627:therapeutic use; D005215:Fasting / Q000097:blood; D005260:Female; D054439:Ghrelin / Q000097:blood*; D005947:Glucose / Q000008:administration & dosage* / Q000493:pharmacokinetics; D005951:Glucose Tolerance Test / Q000379:methods; D006801:Humans; D007328:Insulin / Q000097:blood; D020738:Leptin / Q000097:blood*; D008297:Male; D010879:Piperazines / Q000008:administration & dosage / Q000627:therapeutic use; D015363:Quinolones / Q000008:administration & dosage / Q000627:therapeutic use; D018967:Risperidone / Q000008:administration & dosage / Q000627:therapeutic use; D012737:Sex Factors; D013997:Time Factors; D015430:Weight Gain / Q000187:drug effects
D014150:Antipsychotic Agents; D001786:Blood Glucose; D054439:Ghrelin; D007328:Insulin; D020738:Leptin; D010879:Piperazines; D015363:Quinolones; D000068180:Aripiprazole; D005947:Glucose; D018967:Risperidone; D002746:Chlorpromazine